Algiax Pharmaceuticals Names New Executive Team, Decides Clinical Trial Plan for Lead Candidate AP-325
10 May 2019 - - German biotechnology company Algiax Pharmaceuticals has appointed Dr. Ingo Lehrke as CEO and Dr. Guido Koopmans as CSO, the company said.

Dr. Lehrke takes over from co-founder and shareholder Dr. Jürgen Schumacher who becomes chairman of Algiax´ new advisory board.

Lehrke served for the last ten years as Managing director of tesa Labtec GmbH, a drug delivery company that is part of the Beiersdorf Group of companies.

Before that he was managing director and shareholder of Labtec GmbH which was acquired by tesa SE in 2008.

Dr. Koopmans is neuroscientist and holds a PhD in Biological Health Science. He co-founded Algiax Pharmaceuticals and developed AP-325 from bench to bedside.

The company further announced that it intends to start a phase IIa clinical study for its lead candidate AP-325 in chronic neuropathic pain.

Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need. Algiax' lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain.

Next to AP-325 Algiax has discovered novel GABAA receptor modulator compounds called Thioacrylamide derivatives.

The company is advancing a selection of ThAcs derivatives from its discovery to preclinical characterisation